| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 134 | 2024 | 1455 | 13.220 |
Why?
|
| Lung Neoplasms | 29 | 2024 | 547 | 5.580 |
Why?
|
| Lung | 54 | 2024 | 825 | 5.360 |
Why?
|
| Multiple Pulmonary Nodules | 13 | 2020 | 17 | 4.630 |
Why?
|
| Radiography, Thoracic | 31 | 2024 | 100 | 3.580 |
Why?
|
| Diagnostic Imaging | 16 | 2024 | 242 | 3.080 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 322 | 2.920 |
Why?
|
| Radiation Dosage | 11 | 2014 | 120 | 2.680 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2019 | 17 | 2.660 |
Why?
|
| Radiology | 12 | 2024 | 230 | 2.410 |
Why?
|
| Pulmonary Emphysema | 12 | 2019 | 86 | 2.370 |
Why?
|
| Lung Diseases | 21 | 2013 | 163 | 2.250 |
Why?
|
| Radiation Protection | 7 | 2014 | 23 | 1.890 |
Why?
|
| Radiographic Image Enhancement | 8 | 2013 | 98 | 1.660 |
Why?
|
| Humans | 209 | 2024 | 59328 | 1.580 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2015 | 2034 | 1.540 |
Why?
|
| Lung Diseases, Interstitial | 10 | 2023 | 95 | 1.530 |
Why?
|
| Authorship | 3 | 2018 | 22 | 1.400 |
Why?
|
| Periodicals as Topic | 8 | 2013 | 172 | 1.330 |
Why?
|
| Diagnosis, Differential | 33 | 2020 | 895 | 1.270 |
Why?
|
| Thoracic Diseases | 5 | 2014 | 13 | 1.250 |
Why?
|
| Respiratory Function Tests | 20 | 2020 | 165 | 1.200 |
Why?
|
| Aged | 67 | 2021 | 13293 | 1.190 |
Why?
|
| Clinical Competence | 5 | 2024 | 677 | 1.160 |
Why?
|
| Biomedical Research | 3 | 2018 | 250 | 1.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 11 | 2019 | 564 | 1.080 |
Why?
|
| Male | 98 | 2021 | 27509 | 1.060 |
Why?
|
| Female | 105 | 2021 | 30827 | 1.060 |
Why?
|
| Incidental Findings | 5 | 2017 | 40 | 1.010 |
Why?
|
| Pulmonary Fibrosis | 7 | 2012 | 53 | 1.000 |
Why?
|
| Pulmonary Embolism | 11 | 2014 | 169 | 0.990 |
Why?
|
| Publishing | 4 | 2018 | 89 | 0.980 |
Why?
|
| Observer Variation | 15 | 2019 | 201 | 0.950 |
Why?
|
| Middle Aged | 79 | 2020 | 16238 | 0.940 |
Why?
|
| Pulmonary Artery | 4 | 2022 | 90 | 0.920 |
Why?
|
| Terminology as Topic | 4 | 2013 | 138 | 0.920 |
Why?
|
| Algorithms | 9 | 2019 | 986 | 0.910 |
Why?
|
| Sensitivity and Specificity | 28 | 2017 | 1093 | 0.910 |
Why?
|
| Adult | 81 | 2020 | 15735 | 0.910 |
Why?
|
| Practice Guidelines as Topic | 10 | 2017 | 704 | 0.890 |
Why?
|
| Paraproteinemias | 2 | 2014 | 18 | 0.880 |
Why?
|
| Educational Measurement | 1 | 2024 | 207 | 0.820 |
Why?
|
| Reproducibility of Results | 20 | 2017 | 1549 | 0.820 |
Why?
|
| Radiation Injuries | 2 | 2013 | 55 | 0.820 |
Why?
|
| Phantoms, Imaging | 6 | 2024 | 210 | 0.790 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2020 | 107 | 0.790 |
Why?
|
| Bronchi | 7 | 2020 | 77 | 0.780 |
Why?
|
| Multidetector Computed Tomography | 4 | 2014 | 20 | 0.770 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 451 | 0.760 |
Why?
|
| Respiratory Mechanics | 6 | 2012 | 50 | 0.730 |
Why?
|
| Radiologists | 2 | 2024 | 74 | 0.730 |
Why?
|
| Thoracic Neoplasms | 3 | 2015 | 12 | 0.730 |
Why?
|
| Critical Care | 8 | 1999 | 406 | 0.720 |
Why?
|
| Bronchial Diseases | 4 | 2015 | 8 | 0.720 |
Why?
|
| Bronchiolitis Obliterans | 4 | 2010 | 17 | 0.720 |
Why?
|
| Curriculum | 1 | 2024 | 550 | 0.690 |
Why?
|
| Image Enhancement | 9 | 2009 | 190 | 0.680 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2017 | 712 | 0.670 |
Why?
|
| Neoplasm Staging | 10 | 2023 | 450 | 0.660 |
Why?
|
| Retrospective Studies | 24 | 2023 | 5975 | 0.650 |
Why?
|
| Communication | 1 | 2024 | 552 | 0.650 |
Why?
|
| Image Processing, Computer-Assisted | 15 | 2019 | 636 | 0.630 |
Why?
|
| Mediastinum | 2 | 2015 | 23 | 0.590 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2013 | 76 | 0.580 |
Why?
|
| Bronchiolitis | 2 | 2008 | 17 | 0.580 |
Why?
|
| Lung Transplantation | 4 | 2010 | 47 | 0.570 |
Why?
|
| Aged, 80 and over | 25 | 2020 | 5067 | 0.570 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2017 | 43 | 0.560 |
Why?
|
| Forced Expiratory Volume | 7 | 2019 | 148 | 0.550 |
Why?
|
| Internship and Residency | 1 | 2024 | 722 | 0.550 |
Why?
|
| Water | 2 | 2020 | 295 | 0.550 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2014 | 16 | 0.540 |
Why?
|
| Health Care Surveys | 2 | 2017 | 278 | 0.530 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 196 | 0.510 |
Why?
|
| Tracheal Diseases | 1 | 2015 | 8 | 0.500 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 67 | 0.480 |
Why?
|
| Software | 3 | 2015 | 367 | 0.450 |
Why?
|
| Trachea | 2 | 2013 | 92 | 0.450 |
Why?
|
| Breast | 2 | 2014 | 173 | 0.440 |
Why?
|
| Air | 4 | 2010 | 16 | 0.440 |
Why?
|
| Gravitation | 2 | 2010 | 10 | 0.430 |
Why?
|
| Pneumonia | 5 | 2023 | 263 | 0.430 |
Why?
|
| Internationality | 1 | 2013 | 42 | 0.430 |
Why?
|
| Eye Foreign Bodies | 4 | 2000 | 8 | 0.420 |
Why?
|
| Posture | 2 | 2010 | 126 | 0.410 |
Why?
|
| Exhalation | 5 | 2015 | 12 | 0.410 |
Why?
|
| Heart-Lung Transplantation | 2 | 2003 | 4 | 0.410 |
Why?
|
| Consensus | 2 | 2011 | 194 | 0.410 |
Why?
|
| Neoplasms | 3 | 2023 | 1234 | 0.410 |
Why?
|
| Lung Volume Measurements | 4 | 2015 | 15 | 0.410 |
Why?
|
| Bibliometrics | 2 | 2011 | 27 | 0.400 |
Why?
|
| Angiography | 6 | 2009 | 145 | 0.390 |
Why?
|
| Heart Diseases | 2 | 2014 | 204 | 0.390 |
Why?
|
| Pelvis | 1 | 2011 | 57 | 0.380 |
Why?
|
| Pregnancy Complications | 2 | 2014 | 391 | 0.380 |
Why?
|
| Pulmonary Edema | 3 | 2004 | 25 | 0.370 |
Why?
|
| Densitometry | 3 | 2015 | 12 | 0.370 |
Why?
|
| Contrast Media | 10 | 2024 | 408 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 233 | 0.350 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2007 | 67 | 0.350 |
Why?
|
| Catheterization, Central Venous | 4 | 2013 | 85 | 0.350 |
Why?
|
| Oxygen | 5 | 2006 | 307 | 0.350 |
Why?
|
| Orbit | 2 | 2000 | 17 | 0.340 |
Why?
|
| Analysis of Variance | 6 | 2015 | 576 | 0.340 |
Why?
|
| Tomography, Spiral Computed | 3 | 2010 | 21 | 0.340 |
Why?
|
| Prospective Studies | 20 | 2013 | 3095 | 0.340 |
Why?
|
| Editorial Policies | 3 | 2018 | 53 | 0.340 |
Why?
|
| Total Lung Capacity | 4 | 2015 | 9 | 0.340 |
Why?
|
| Tuberculin Test | 1 | 2009 | 10 | 0.330 |
Why?
|
| Mycobacterium xenopi | 2 | 1999 | 2 | 0.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 1999 | 14 | 0.320 |
Why?
|
| Reference Values | 8 | 2015 | 323 | 0.320 |
Why?
|
| Tumor Burden | 2 | 2020 | 62 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 242 | 0.310 |
Why?
|
| Pleural Diseases | 3 | 2012 | 8 | 0.300 |
Why?
|
| Prognosis | 8 | 2023 | 1564 | 0.290 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2007 | 2 | 0.280 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 17 | 0.280 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2006 | 98 | 0.280 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 827 | 0.280 |
Why?
|
| Inflammation | 1 | 2013 | 1101 | 0.270 |
Why?
|
| Spirometry | 5 | 2019 | 94 | 0.270 |
Why?
|
| Disease Progression | 7 | 2020 | 1040 | 0.270 |
Why?
|
| Pulmonary Ventilation | 4 | 2012 | 36 | 0.270 |
Why?
|
| Cystic Fibrosis | 2 | 2010 | 110 | 0.270 |
Why?
|
| Aortic Rupture | 1 | 2006 | 49 | 0.260 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 32 | 0.260 |
Why?
|
| Pulmonary Medicine | 2 | 2008 | 25 | 0.260 |
Why?
|
| Bronchiectasis | 2 | 2019 | 9 | 0.250 |
Why?
|
| Cysts | 2 | 2010 | 37 | 0.250 |
Why?
|
| Dyspnea | 1 | 2006 | 108 | 0.240 |
Why?
|
| Thoracic Injuries | 2 | 2003 | 48 | 0.240 |
Why?
|
| Bronchoscopy | 2 | 2008 | 64 | 0.240 |
Why?
|
| Biopsy | 7 | 2008 | 373 | 0.230 |
Why?
|
| Aorta | 2 | 2009 | 103 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2006 | 276 | 0.220 |
Why?
|
| Collagen Diseases | 1 | 2003 | 4 | 0.220 |
Why?
|
| Metals | 3 | 2000 | 63 | 0.220 |
Why?
|
| Artifacts | 5 | 2013 | 126 | 0.220 |
Why?
|
| Immunoconjugates | 1 | 2023 | 84 | 0.210 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 2588 | 0.210 |
Why?
|
| Eye Injuries, Penetrating | 2 | 1999 | 5 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2001 | 1130 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2021 | 80 | 0.200 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2002 | 1 | 0.200 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2010 | 24 | 0.200 |
Why?
|
| Tracheomalacia | 2 | 2013 | 5 | 0.200 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 172 | 0.200 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 53 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 741 | 0.190 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 304 | 0.190 |
Why?
|
| Logistic Models | 2 | 2018 | 1252 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 59 | 0.190 |
Why?
|
| Carcinoma | 1 | 2002 | 117 | 0.190 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2006 | 180 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 135 | 0.180 |
Why?
|
| Anterior Cruciate Ligament Injuries | 2 | 1998 | 23 | 0.180 |
Why?
|
| Young Adult | 4 | 2020 | 4320 | 0.180 |
Why?
|
| Radiography | 8 | 2010 | 505 | 0.180 |
Why?
|
| Patient Care Management | 1 | 2021 | 28 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 42 | 0.180 |
Why?
|
| Fistula | 2 | 1999 | 12 | 0.180 |
Why?
|
| Knee Injuries | 2 | 1998 | 47 | 0.180 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 403 | 0.180 |
Why?
|
| Lymphangioma, Cystic | 1 | 2000 | 2 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2024 | 837 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 118 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 77 | 0.170 |
Why?
|
| Orbital Diseases | 1 | 2000 | 9 | 0.170 |
Why?
|
| Hemoptysis | 1 | 2000 | 6 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2010 | 324 | 0.170 |
Why?
|
| Bronchial Fistula | 1 | 1999 | 4 | 0.170 |
Why?
|
| Cutaneous Fistula | 1 | 1999 | 7 | 0.170 |
Why?
|
| Cytodiagnosis | 1 | 2020 | 43 | 0.170 |
Why?
|
| Mineral Oil | 1 | 1999 | 5 | 0.170 |
Why?
|
| Hydrocarbons | 1 | 1999 | 8 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2015 | 265 | 0.170 |
Why?
|
| Vitrectomy | 1 | 1999 | 19 | 0.170 |
Why?
|
| Respiration Disorders | 2 | 2010 | 20 | 0.170 |
Why?
|
| Pregnancy | 5 | 2014 | 2352 | 0.160 |
Why?
|
| Brain Damage, Chronic | 1 | 1999 | 5 | 0.160 |
Why?
|
| Oils | 1 | 1999 | 70 | 0.160 |
Why?
|
| Absorptiometry, Photon | 1 | 1999 | 89 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 151 | 0.160 |
Why?
|
| Neuroradiography | 1 | 1998 | 10 | 0.160 |
Why?
|
| Research Design | 2 | 2013 | 565 | 0.160 |
Why?
|
| Supine Position | 2 | 2010 | 31 | 0.160 |
Why?
|
| Prone Position | 2 | 2010 | 27 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2001 | 316 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 2 | 2014 | 13 | 0.150 |
Why?
|
| Abnormalities, Multiple | 1 | 1998 | 52 | 0.150 |
Why?
|
| Statistics, Nonparametric | 3 | 2008 | 208 | 0.150 |
Why?
|
| Radiography, Abdominal | 2 | 1995 | 27 | 0.150 |
Why?
|
| Heart | 2 | 2010 | 274 | 0.150 |
Why?
|
| Pneumonia, Bacterial | 1 | 1998 | 86 | 0.150 |
Why?
|
| Adolescent | 15 | 2014 | 5917 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1998 | 168 | 0.140 |
Why?
|
| Tuberculosis, Female Genital | 2 | 1995 | 2 | 0.140 |
Why?
|
| Azygos Vein | 1 | 1997 | 4 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1997 | 24 | 0.140 |
Why?
|
| Ovarian Diseases | 2 | 1995 | 20 | 0.140 |
Why?
|
| Time Factors | 6 | 2014 | 3567 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 424 | 0.140 |
Why?
|
| Ventilation-Perfusion Ratio | 3 | 2002 | 9 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 119 | 0.140 |
Why?
|
| Bronchography | 1 | 1996 | 2 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2010 | 156 | 0.130 |
Why?
|
| Vital Capacity | 3 | 2019 | 73 | 0.130 |
Why?
|
| Acute Disease | 5 | 2009 | 658 | 0.130 |
Why?
|
| Pulmonary Atelectasis | 1 | 2015 | 9 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1024 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 72 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 137 | 0.130 |
Why?
|
| Aortography | 2 | 2009 | 53 | 0.130 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 35 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1225 | 0.120 |
Why?
|
| Medical Errors | 1 | 1997 | 193 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 1995 | 80 | 0.120 |
Why?
|
| Prevalence | 3 | 2020 | 1279 | 0.120 |
Why?
|
| Mediastinal Diseases | 1 | 2014 | 13 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 1995 | 77 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 1995 | 92 | 0.120 |
Why?
|
| Smoking | 3 | 2023 | 830 | 0.120 |
Why?
|
| Craniocerebral Trauma | 1 | 1995 | 58 | 0.120 |
Why?
|
| Linear Models | 3 | 2019 | 419 | 0.120 |
Why?
|
| Candidiasis | 1 | 1994 | 40 | 0.120 |
Why?
|
| Surgical Sponges | 1 | 2014 | 1 | 0.110 |
Why?
|
| Geography | 1 | 2013 | 32 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2014 | 35 | 0.110 |
Why?
|
| Age Factors | 3 | 2015 | 1518 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 151 | 0.110 |
Why?
|
| Journal Impact Factor | 1 | 2013 | 17 | 0.110 |
Why?
|
| Models, Anatomic | 1 | 2014 | 55 | 0.110 |
Why?
|
| Noise | 1 | 2014 | 33 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2009 | 1061 | 0.110 |
Why?
|
| Fetus | 1 | 2014 | 97 | 0.110 |
Why?
|
| Journalism, Medical | 1 | 2013 | 4 | 0.110 |
Why?
|
| Lactation | 1 | 2014 | 70 | 0.110 |
Why?
|
| Venae Cavae | 1 | 2013 | 2 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2013 | 46 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2011 | 211 | 0.110 |
Why?
|
| Central Venous Catheters | 1 | 2013 | 17 | 0.100 |
Why?
|
| Pneumonectomy | 2 | 2012 | 82 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2015 | 189 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2017 | 1907 | 0.100 |
Why?
|
| Cadaver | 3 | 2000 | 102 | 0.100 |
Why?
|
| Jugular Veins | 3 | 1998 | 30 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 126 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2013 | 168 | 0.100 |
Why?
|
| Heart Atria | 1 | 2013 | 137 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2007 | 2323 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 1993 | 133 | 0.100 |
Why?
|
| Emphysema | 1 | 2012 | 29 | 0.100 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2011 | 1 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 1995 | 447 | 0.100 |
Why?
|
| Tuberculosis | 1 | 1995 | 262 | 0.100 |
Why?
|
| Radiometry | 1 | 2011 | 34 | 0.100 |
Why?
|
| Mediastinoscopy | 1 | 2011 | 6 | 0.090 |
Why?
|
| Risk Factors | 6 | 2020 | 4999 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2009 | 94 | 0.090 |
Why?
|
| Patient Safety | 1 | 2014 | 243 | 0.090 |
Why?
|
| Bronchomalacia | 1 | 2010 | 1 | 0.090 |
Why?
|
| Peer Review | 1 | 2011 | 25 | 0.090 |
Why?
|
| Drainage | 2 | 2006 | 144 | 0.090 |
Why?
|
| Plethysmography, Whole Body | 1 | 2009 | 2 | 0.090 |
Why?
|
| Helium | 1 | 2009 | 7 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 1448 | 0.090 |
Why?
|
| Blood Gas Analysis | 2 | 2008 | 34 | 0.090 |
Why?
|
| Anus Neoplasms | 1 | 2009 | 21 | 0.080 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 34 | 0.080 |
Why?
|
| Mass Screening | 1 | 2014 | 643 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2011 | 283 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2000 | 1838 | 0.080 |
Why?
|
| Patient Positioning | 3 | 2014 | 41 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2001 | 50 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2004 | 258 | 0.080 |
Why?
|
| Phlebography | 3 | 1999 | 43 | 0.080 |
Why?
|
| ROC Curve | 3 | 2013 | 259 | 0.080 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2008 | 5 | 0.080 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 86 | 0.080 |
Why?
|
| Perfusion | 1 | 2008 | 77 | 0.080 |
Why?
|
| Recurrence | 3 | 2006 | 576 | 0.080 |
Why?
|
| Biomarkers | 1 | 2013 | 1205 | 0.080 |
Why?
|
| United States | 5 | 2017 | 7494 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2006 | 109 | 0.080 |
Why?
|
| Carpal Bones | 2 | 1998 | 3 | 0.070 |
Why?
|
| Wrist Injuries | 2 | 1998 | 11 | 0.070 |
Why?
|
| Breath Tests | 1 | 2007 | 14 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 847 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 295 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2019 | 732 | 0.070 |
Why?
|
| Emergencies | 2 | 2006 | 114 | 0.070 |
Why?
|
| Tuberculoma | 1 | 2007 | 1 | 0.070 |
Why?
|
| Tuberculosis, Miliary | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pulmonary Circulation | 3 | 2004 | 23 | 0.070 |
Why?
|
| Occupational Health | 1 | 2009 | 186 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 158 | 0.070 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 17 | 0.070 |
Why?
|
| Fatal Outcome | 3 | 2009 | 112 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 158 | 0.070 |
Why?
|
| Nails | 1 | 2007 | 38 | 0.070 |
Why?
|
| Sjogren's Syndrome | 2 | 2010 | 26 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 141 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2007 | 45 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2006 | 21 | 0.070 |
Why?
|
| Data Compression | 1 | 2006 | 9 | 0.070 |
Why?
|
| Embolization, Therapeutic | 2 | 2001 | 307 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2006 | 76 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2006 | 66 | 0.070 |
Why?
|
| Sex Factors | 2 | 2007 | 959 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2006 | 133 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 124 | 0.060 |
Why?
|
| Child | 6 | 2000 | 4300 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2005 | 9 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2005 | 14 | 0.060 |
Why?
|
| Radiography, Interventional | 3 | 2013 | 67 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2005 | 27 | 0.060 |
Why?
|
| Pyrazines | 1 | 2005 | 32 | 0.060 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2002 | 83 | 0.060 |
Why?
|
| Stents | 1 | 2008 | 436 | 0.060 |
Why?
|
| Varicose Veins | 2 | 1996 | 7 | 0.060 |
Why?
|
| Ethiodized Oil | 1 | 2024 | 6 | 0.060 |
Why?
|
| Enbucrilate | 1 | 2024 | 9 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2005 | 522 | 0.060 |
Why?
|
| Dilatation, Pathologic | 2 | 2009 | 28 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2007 | 4 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 846 | 0.060 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 320 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2004 | 12 | 0.060 |
Why?
|
| Thalidomide | 1 | 2004 | 33 | 0.060 |
Why?
|
| Mitosporic Fungi | 1 | 2004 | 2 | 0.060 |
Why?
|
| Extravascular Lung Water | 1 | 2004 | 3 | 0.060 |
Why?
|
| Dermatomycoses | 1 | 2004 | 13 | 0.060 |
Why?
|
| Swine | 1 | 2024 | 338 | 0.060 |
Why?
|
| Fingers | 2 | 2007 | 42 | 0.060 |
Why?
|
| Rats | 1 | 2007 | 1907 | 0.050 |
Why?
|
| Decision Making | 1 | 2006 | 388 | 0.050 |
Why?
|
| Heart Arrest | 2 | 2002 | 155 | 0.050 |
Why?
|
| Renal Circulation | 2 | 1999 | 10 | 0.050 |
Why?
|
| HIV Infections | 1 | 2009 | 919 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 404 | 0.050 |
Why?
|
| Animals | 4 | 2024 | 19613 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 301 | 0.050 |
Why?
|
| Models, Biological | 3 | 2012 | 1140 | 0.050 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cause of Death | 1 | 2002 | 200 | 0.050 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2001 | 14 | 0.050 |
Why?
|
| Laryngoscopy | 1 | 2002 | 60 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2001 | 64 | 0.050 |
Why?
|
| Anterior Cruciate Ligament | 2 | 1998 | 12 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 262 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2001 | 101 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2021 | 91 | 0.040 |
Why?
|
| Infant | 3 | 2000 | 1527 | 0.040 |
Why?
|
| Occupations | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 38 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2000 | 18 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 65 | 0.040 |
Why?
|
| Bronchitis | 1 | 2000 | 25 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 97 | 0.040 |
Why?
|
| Paraffin | 1 | 1999 | 2 | 0.040 |
Why?
|
| Traction | 1 | 2019 | 4 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 404 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 1998 | 25 | 0.040 |
Why?
|
| Fires | 1 | 1999 | 12 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2062 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2007 | 5142 | 0.040 |
Why?
|
| Infarction | 1 | 1999 | 20 | 0.040 |
Why?
|
| Pneumothorax | 2 | 1997 | 42 | 0.040 |
Why?
|
| Thorax | 1 | 1999 | 34 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 870 | 0.040 |
Why?
|
| Respiration | 2 | 2000 | 87 | 0.040 |
Why?
|
| Ultrasonography | 2 | 1998 | 449 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 151 | 0.040 |
Why?
|
| Cholecystography | 1 | 1998 | 14 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 1998 | 25 | 0.040 |
Why?
|
| Cholecystitis | 1 | 1998 | 29 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 643 | 0.040 |
Why?
|
| Diagnostic Errors | 2 | 1996 | 98 | 0.040 |
Why?
|
| Eye Injuries | 1 | 1998 | 14 | 0.040 |
Why?
|
| Toes | 1 | 1998 | 13 | 0.040 |
Why?
|
| Face | 1 | 1998 | 34 | 0.040 |
Why?
|
| Renal Veins | 1 | 1998 | 6 | 0.040 |
Why?
|
| Syndrome | 1 | 1998 | 173 | 0.040 |
Why?
|
| Renal Artery | 1 | 1998 | 29 | 0.040 |
Why?
|
| Near Drowning | 1 | 1997 | 1 | 0.040 |
Why?
|
| Tibial Meniscus Injuries | 1 | 1998 | 13 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1129 | 0.040 |
Why?
|
| Pulmonary Surfactants | 1 | 1997 | 9 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2001 | 249 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 399 | 0.040 |
Why?
|
| Pleura | 1 | 1997 | 11 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 1999 | 117 | 0.040 |
Why?
|
| Phospholipids | 1 | 1997 | 79 | 0.040 |
Why?
|
| SEER Program | 1 | 2017 | 63 | 0.040 |
Why?
|
| Subclavian Vein | 1 | 1997 | 11 | 0.040 |
Why?
|
| Rupture | 1 | 1997 | 22 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1997 | 27 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 1997 | 27 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 278 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1997 | 35 | 0.030 |
Why?
|
| Caplan Syndrome | 1 | 1996 | 1 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2010 | 331 | 0.030 |
Why?
|
| Weil Disease | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 287 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 7 | 0.030 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2016 | 3 | 0.030 |
Why?
|
| Attitude | 1 | 1997 | 99 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 1997 | 137 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 17 | 0.030 |
Why?
|
| Cholangiography | 1 | 1996 | 42 | 0.030 |
Why?
|
| Diuresis | 1 | 1996 | 4 | 0.030 |
Why?
|
| Hydronephrosis | 1 | 1996 | 7 | 0.030 |
Why?
|
| Biological Products | 1 | 1997 | 94 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1995 | 11 | 0.030 |
Why?
|
| Technology, Radiologic | 1 | 1995 | 9 | 0.030 |
Why?
|
| Cholestasis | 1 | 1996 | 52 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1996 | 46 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1997 | 257 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 304 | 0.030 |
Why?
|
| Automation | 1 | 1995 | 58 | 0.030 |
Why?
|
| Tuberculosis, Splenic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Peritonitis, Tuberculous | 1 | 1995 | 2 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 1995 | 59 | 0.030 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1995 | 4 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1996 | 475 | 0.030 |
Why?
|
| Thoracostomy | 1 | 1995 | 8 | 0.030 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 1995 | 5 | 0.030 |
Why?
|
| Chest Tubes | 1 | 1995 | 14 | 0.030 |
Why?
|
| Ascites | 1 | 1995 | 21 | 0.030 |
Why?
|
| Hypoxia, Brain | 1 | 1995 | 9 | 0.030 |
Why?
|
| Tracheal Stenosis | 1 | 1995 | 6 | 0.030 |
Why?
|
| Internet | 1 | 1999 | 458 | 0.030 |
Why?
|
| Brain Edema | 1 | 1995 | 31 | 0.030 |
Why?
|
| Skull | 1 | 1995 | 57 | 0.030 |
Why?
|
| Belgium | 1 | 2014 | 6 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1995 | 63 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 2 | 2009 | 11 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 1995 | 127 | 0.030 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1994 | 15 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 1994 | 37 | 0.030 |
Why?
|
| Silicones | 1 | 1994 | 11 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 485 | 0.030 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1995 | 106 | 0.030 |
Why?
|
| Echocardiography | 1 | 1997 | 455 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1998 | 1311 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 1994 | 63 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 74 | 0.030 |
Why?
|
| Mammaplasty | 1 | 1994 | 44 | 0.030 |
Why?
|
| Anxiety | 1 | 1997 | 395 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 329 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 8 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1994 | 110 | 0.030 |
Why?
|
| Airway Resistance | 1 | 2012 | 8 | 0.030 |
Why?
|
| Breath Holding | 1 | 2012 | 7 | 0.030 |
Why?
|
| Spin Labels | 2 | 2002 | 12 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 2011 | 11 | 0.020 |
Why?
|
| Survival Rate | 2 | 2004 | 787 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 2010 | 1 | 0.020 |
Why?
|
| Neurofibromatoses | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 7 | 0.020 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2010 | 12 | 0.020 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 14 | 0.020 |
Why?
|
| Fourier Analysis | 2 | 2001 | 32 | 0.020 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2010 | 14 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 170 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1990 | 56 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 41 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 200 | 0.020 |
Why?
|
| Kidney | 3 | 1998 | 391 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1994 | 354 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 2009 | 3 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 66 | 0.020 |
Why?
|
| Bronchioles | 1 | 2009 | 4 | 0.020 |
Why?
|
| Amyloidosis | 1 | 2010 | 58 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 523 | 0.020 |
Why?
|
| Cachexia | 1 | 2009 | 9 | 0.020 |
Why?
|
| Groin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 163 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1990 | 228 | 0.020 |
Why?
|
| Arteriovenous Fistula | 2 | 2001 | 39 | 0.020 |
Why?
|
| Brain | 1 | 1998 | 1488 | 0.020 |
Why?
|
| Anal Canal | 1 | 2009 | 34 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 1990 | 181 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2010 | 161 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 82 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2437 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2010 | 226 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Myocardium | 1 | 2010 | 262 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2008 | 51 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 153 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 456 | 0.020 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2007 | 4 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 94 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 2007 | 31 | 0.020 |
Why?
|
| Aspergillosis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Jews | 1 | 2006 | 14 | 0.020 |
Why?
|
| Israel | 1 | 2006 | 18 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 525 | 0.020 |
Why?
|
| Gestational Age | 1 | 2007 | 182 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 77 | 0.020 |
Why?
|
| Equipment Design | 2 | 1997 | 314 | 0.020 |
Why?
|
| Bortezomib | 1 | 2005 | 54 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2005 | 73 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 137 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2007 | 454 | 0.020 |
Why?
|
| Hydrostatic Pressure | 1 | 2004 | 4 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 60 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2004 | 22 | 0.010 |
Why?
|
| Rituximab | 1 | 2004 | 82 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 220 | 0.010 |
Why?
|
| Austria | 1 | 2002 | 6 | 0.010 |
Why?
|
| Dogs | 1 | 2004 | 316 | 0.010 |
Why?
|
| Heart Massage | 1 | 2001 | 3 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2001 | 24 | 0.010 |
Why?
|
| Compliance | 1 | 2001 | 5 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 2001 | 12 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2002 | 180 | 0.010 |
Why?
|
| Arteriovenous Malformations | 1 | 2001 | 42 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2001 | 107 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 2463 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 199 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 69 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 28 | 0.010 |
Why?
|
| Iliac Artery | 1 | 2000 | 46 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 148 | 0.010 |
Why?
|
| Rheology | 1 | 2000 | 65 | 0.010 |
Why?
|
| Proteinuria | 1 | 1999 | 37 | 0.010 |
Why?
|
| Hematuria | 1 | 1999 | 18 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2002 | 285 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1999 | 19 | 0.010 |
Why?
|
| Veins | 1 | 1999 | 61 | 0.010 |
Why?
|
| Medical Records | 1 | 1999 | 137 | 0.010 |
Why?
|
| Hypermedia | 1 | 1999 | 2 | 0.010 |
Why?
|
| Radiology Information Systems | 1 | 1999 | 28 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1999 | 124 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 164 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1998 | 25 | 0.010 |
Why?
|
| Urinary Fistula | 1 | 1998 | 8 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1998 | 126 | 0.010 |
Why?
|
| Menisci, Tibial | 1 | 1998 | 25 | 0.010 |
Why?
|
| Aneurysm, False | 1 | 1998 | 45 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1998 | 133 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1998 | 174 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1998 | 69 | 0.010 |
Why?
|
| Diazepam | 1 | 1997 | 11 | 0.010 |
Why?
|
| Phobic Disorders | 1 | 1997 | 15 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1998 | 67 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 1997 | 31 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2000 | 222 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1997 | 103 | 0.010 |
Why?
|
| Motion | 1 | 1997 | 55 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1997 | 174 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1998 | 157 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1997 | 232 | 0.010 |
Why?
|
| Radioisotope Renography | 1 | 1996 | 4 | 0.010 |
Why?
|
| Incidence | 1 | 1999 | 1232 | 0.010 |
Why?
|
| Furosemide | 1 | 1996 | 17 | 0.010 |
Why?
|
| Ureteral Obstruction | 1 | 1996 | 11 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 684 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1996 | 44 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 1996 | 34 | 0.010 |
Why?
|
| Causality | 1 | 1996 | 56 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1996 | 43 | 0.010 |
Why?
|
| Hemothorax | 1 | 1995 | 9 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 485 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1996 | 354 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 139 | 0.010 |
Why?
|
| Ultrasonography, Mammary | 1 | 1994 | 16 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1994 | 187 | 0.010 |
Why?
|
| Patient Selection | 1 | 1996 | 445 | 0.010 |
Why?
|
| Reoperation | 1 | 1994 | 249 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1994 | 107 | 0.010 |
Why?
|
| Palliative Care | 1 | 1994 | 202 | 0.010 |
Why?
|
| Liver | 1 | 1996 | 785 | 0.010 |
Why?
|
| Mammography | 1 | 1994 | 272 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 53 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1990 | 148 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1990 | 82 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1990 | 56 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1990 | 265 | 0.010 |
Why?
|
| Base Sequence | 1 | 1990 | 1312 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1990 | 1582 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1990 | 1977 | 0.000 |
Why?
|
| Cell Line | 1 | 1990 | 2014 | 0.000 |
Why?
|